- Home
- ALVR vs PNI Comparison
ALVR vs PNI Comparison
Compare ALVR & PNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- PNI
- Stock Information
- Founded
- ALVR 2013
- PNI 2002
- Country
- ALVR United States
- PNI United States
- Employees
- ALVR N/A
- PNI N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- PNI Trusts Except Educational Religious and Charitable
- Sector
- ALVR Health Care
- PNI Finance
- Exchange
- ALVR Nasdaq
- PNI Nasdaq
- Market Cap
- ALVR 87.7M
- PNI 84.2M
- IPO Year
- ALVR 2020
- PNI N/A
- Fundamental
- Price
- ALVR $0.76
- PNI $7.66
- Analyst Decision
- ALVR Sell
- PNI
- Analyst Count
- ALVR 4
- PNI 0
- Target Price
- ALVR $1.17
- PNI N/A
- AVG Volume (30 Days)
- ALVR 147.4K
- PNI 26.4K
- Earning Date
- ALVR 10-31-2024
- PNI 01-01-0001
- Dividend Yield
- ALVR N/A
- PNI 4.76%
- EPS Growth
- ALVR N/A
- PNI N/A
- EPS
- ALVR N/A
- PNI N/A
- Revenue
- ALVR N/A
- PNI N/A
- Revenue This Year
- ALVR N/A
- PNI N/A
- Revenue Next Year
- ALVR N/A
- PNI N/A
- P/E Ratio
- ALVR N/A
- PNI N/A
- Revenue Growth
- ALVR N/A
- PNI N/A
- 52 Week Low
- ALVR $0.58
- PNI $6.03
- 52 Week High
- ALVR $2.93
- PNI $7.89
- Technical
- Relative Strength Index (RSI)
- ALVR 51.29
- PNI 70.24
- Support Level
- ALVR $0.76
- PNI $7.55
- Resistance Level
- ALVR $0.80
- PNI $7.62
- Average True Range (ATR)
- ALVR 0.03
- PNI 0.05
- MACD
- ALVR 0.00
- PNI 0.01
- Stochastic Oscillator
- ALVR 61.09
- PNI 88.89
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.